O M Kew

Summary

Affiliation: Centers for Disease Control and Prevention
Country: USA

Publications

  1. ncbi Polio eradication: the OPV paradox
    Walter R Dowdle
    Task Force for Child Survival and Development, Decatur, GA 30030, USA
    Rev Med Virol 13:277-91. 2003
  2. ncbi Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient
    O M Kew
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 36:2893-9. 1998
  3. ncbi Vaccine-derived polioviruses and the endgame strategy for global polio eradication
    Olen M Kew
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Annu Rev Microbiol 59:587-635. 2005
  4. ncbi Circulating vaccine-derived polioviruses: current state of knowledge
    Olen M Kew
    WHO Global Specialized Reference Laboratory, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Bull World Health Organ 82:16-23. 2004
  5. ncbi Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residue at positions of codon degeneracy
    D R Kilpatrick
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Center for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 34:2990-6. 1996
  6. ncbi Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China
    H M Liu
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Virol 74:11153-61. 2000
  7. ncbi Poliovirus vaccine shedding among persons with HIV in Abidjan, Cote d'Ivoire
    Karen A Hennessey
    Global Immunization Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30309, USA
    J Infect Dis 192:2124-8. 2005
  8. ncbi Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication
    Radboud J Duintjer Tebbens
    Kids Risk Project, Harvard School of Public Health, Boston, MA, USA
    Risk Anal 26:1471-505. 2006
  9. ncbi Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling
    Kimberly M Thompson
    Kids Risk Project, Harvard School of Public Health, 677 Huntington Ave, 3rd Floor, Boston, MA 02115, USA
    Risk Anal 26:1571-80. 2006
  10. ncbi Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency
    Nima Parvaneh
    Department of Pediatrics, Infectious Disease Research Center, Children s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
    J Clin Virol 39:145-8. 2007

Collaborators

Detail Information

Publications21

  1. ncbi Polio eradication: the OPV paradox
    Walter R Dowdle
    Task Force for Child Survival and Development, Decatur, GA 30030, USA
    Rev Med Virol 13:277-91. 2003
    ....
  2. ncbi Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient
    O M Kew
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 36:2893-9. 1998
    ..These findings may have important implications for the strategy to eliminate poliovirus immunization after global polio eradication...
  3. ncbi Vaccine-derived polioviruses and the endgame strategy for global polio eradication
    Olen M Kew
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Annu Rev Microbiol 59:587-635. 2005
    ..Developing a posteradication strategy to minimize the risks of VDPV emergence and spread has become an urgent WHO priority...
  4. ncbi Circulating vaccine-derived polioviruses: current state of knowledge
    Olen M Kew
    WHO Global Specialized Reference Laboratory, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Bull World Health Organ 82:16-23. 2004
    ..Particular attention must be given to areas where the risks for wild poliovirus circulation have been highest, and where the highest rates of polio vaccine coverage must be maintained to suppress cVDPV emergence...
  5. ncbi Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residue at positions of codon degeneracy
    D R Kilpatrick
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Center for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Clin Microbiol 34:2990-6. 1996
    ..These degenerate PCR primers should aid in the detection of all polioviruses, including those wild poliovirus isolates for which genotype-specific reagents are unavailable...
  6. ncbi Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China
    H M Liu
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Virol 74:11153-61. 2000
    ....
  7. ncbi Poliovirus vaccine shedding among persons with HIV in Abidjan, Cote d'Ivoire
    Karen A Hennessey
    Global Immunization Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30309, USA
    J Infect Dis 192:2124-8. 2005
    ..The present study was conducted to assess whether persons infected with human immunodeficiency virus (HIV) experience prolonged VDPV shedding and serve as a source of reintroduction of virus into the population...
  8. ncbi Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication
    Radboud J Duintjer Tebbens
    Kids Risk Project, Harvard School of Public Health, Boston, MA, USA
    Risk Anal 26:1471-505. 2006
    ..This article attempts to comprehensively characterize the risks, synthesize the existing data available for modeling them, and present quantitative risk estimates that can provide a starting point for informing policy decisions...
  9. ncbi Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling
    Kimberly M Thompson
    Kids Risk Project, Harvard School of Public Health, 677 Huntington Ave, 3rd Floor, Boston, MA 02115, USA
    Risk Anal 26:1571-80. 2006
    ..This analytical journey has provided several key insights and lessons learned that will be useful to future analysts involved in similar complex decision-making processes...
  10. ncbi Vaccine-associated paralytic poliomyelitis in a patient with MHC class II deficiency
    Nima Parvaneh
    Department of Pediatrics, Infectious Disease Research Center, Children s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
    J Clin Virol 39:145-8. 2007
    ..We describe a fatal case of VAPP in an 8-month-old boy with Major Histocompatibility Class II deficiency. The isolated poliovirus was a Sabin type 2-type 1 recombinant that showed 1.4% VP1 divergence from Sabin type 2...
  11. ncbi Molecular epidemiology of wild poliovirus type 1 circulation in West and Central Africa, from 1997 to 1999, using genotyping with a restriction fragment length polymorphism assay
    Ionela Gouandjika-Vasilache
    Institut Pasteur de Bangui, PO Box BP 923, Bangui, Central African Republic
    Arch Virol 153:409-16. 2008
    ....
  12. ncbi The risks, costs, and benefits of possible future global policies for managing polioviruses
    Kimberly M Thompson
    Kids Risk Project, Harvard School of Public Health, 677 Huntington Ave, Third Floor, Boston, MA 02115, USA
    Am J Public Health 98:1322-30. 2008
    ..We assessed the costs, risks, and benefits of possible future major policy decisions on vaccination, surveillance, response plans, and containment following global eradication of wild polioviruses...
  13. ncbi A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future
    Radboud J Duintjer Tebbens
    KidsRisk Project, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Epidemiol 162:358-72. 2005
    ..The authors expect that this model can provide important insights into the dynamics of future potential poliomyelitis outbreaks and in this way serve as a useful tool for risk assessment...
  14. ncbi Environmental surveillance of wild poliovirus circulation in Egypt--balancing between detection sensitivity and workload
    Tapani Hovi
    Department of Viral Diseases and Immunology, National Public Health Institute KTL, Mannerheimintie 166, 00300 Helsinki, Finland
    J Virol Methods 126:127-34. 2005
    ....
  15. ncbi Vaccine policy changes and epidemiology of poliomyelitis in the United States
    Lorraine Niño Alexander
    National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    JAMA 292:1696-701. 2004
    ..To reduce the VAPP burden, national vaccination policy changed in 1997 from reliance on OPV to options for a sequential schedule of inactivated poliovirus vaccine (IPV) followed by OPV. In 2000, an exclusive IPV schedule was adopted...
  16. ncbi Multiplex PCR method for identifying recombinant vaccine-related polioviruses
    David R Kilpatrick
    Respiratory and Enteric Virus Branch, G 10, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Clin Microbiol 42:4313-5. 2004
    ..Six pairs of Sabin strain-specific recombinant primers were designed to permit rapid screening for VDPV recombinants by PCR...
  17. ncbi Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom
    Neal A Halsey
    Institute for Vaccine Safety, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD 21205, USA
    Bull World Health Organ 82:3-8. 2004
    ..CONCLUSION: Although chronic poliovirus excretion can occur in immunodeficient persons, it appears to be rare...
  18. ncbi Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future
    Ekaterina A Korotkova
    A. N. Belozersky Institute of Physical-Chemical Biology, Moscow State University, Moscow 119899, Russia
    J Virol 77:12460-5. 2003
    ..The high transmissibility of OPV-derived viruses in nonimmune population, documented here, and the known existence of long-term OPV excretors should be also considered in assessing risks of the synchronized global cessation of OPV usage...
  19. ncbi Prolonged detection of indigenous wild polioviruses in sewage from communities in Egypt
    Laila El Bassioni
    Egyptian Organization for Biological Products and Vaccine Production, Cairo, Egypt
    Am J Epidemiol 158:807-15. 2003
    ..Continued analysis of sewage samples, critical evaluation of immunization coverage, and performance of surveillance for acute flaccid paralysis are proposed as follow-up activities...
  20. ncbi Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China
    Hong Mei Liu
    Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Virol 77:10994-1005. 2003
    ..The appearance within approximately 2.5 years of five recombinant classes derived from a single ancestral infection illustrates the rapid emergence of new recombinants among circulating wild polioviruses...
  21. ncbi Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management
    Radboud J Duintjer Tebbens
    Kids Risk Project, Harvard School of Public Health, Boston, MA 02115, USA
    Risk Anal 28:855-76. 2008
    ....